Ruffer LLP’s Jazz Pharmaceuticals JAZZ Stock Holding History

Ruffer LLP’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.91M	Buy	+24,567	New	+$5.38M	0.21%	88
2026 Q1	–	Sell	-14,242	Closed	-$2.42M	–	211
2025 Q4	$2.42M	Buy	+14,242	New	+$2.18M	0.11%	119
2025 Q1	–	Sell	-58,767	Closed	-$7.24M	–	113
2024 Q4	$7.24M	Buy	+58,767	New	+$6.93M	0.26%	51
2024 Q2	–	Sell	-7,702	Closed	-$927K	–	58
2024 Q1	$927K	Hold	7,702	–	–	0.04%	52
2023 Q4	$947K	Hold	7,702	–	–	0.04%	60
2023 Q3	$1.01M	Hold	7,702	–	–	0.06%	58
2023 Q2	$955K	Hold	7,702	–	–	0.06%	57
2023 Q1	$1.13M	Hold	7,702	–	–	0.04%	70
2022 Q4	$1.23M	Hold	7,702	–	–	0.08%	61
2022 Q3	$1.07M	Hold	7,702	–	–	0.07%	72
2022 Q2	$1.2M	Hold	7,702	–	–	0.05%	69
2022 Q1	$1.2M	Hold	7,702	–	–	0.03%	77
2021 Q4	$1.01M	Hold	7,702	–	–	0.02%	76
2021 Q3	$996K	Hold	7,702	–	–	0.03%	68
2021 Q2	$1.37M	Buy	+7,702	New	+$1.33M	0.04%	61

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Ruffer LLP's JAZZ Position: Q2 2026 in Review

Ruffer LLP opened a new position in Jazz Pharmaceuticals (JAZZ) in Q2 2026: 24,567 shares worth $5.91M. The stake represents 0.21% of the portfolio and ranks #88 among its holdings. This is a return to the name: Ruffer LLP previously reported a position in JAZZ as recently as Q4 2025.

Ruffer LLP first reported a position in JAZZ in Q2 2021 and has held it in 15 quarters since. The position peaked at $7.24M in Q4 2024. 646 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

Ruffer LLP held 24,567 shares of Jazz Pharmaceuticals worth $5.91M as of Q2 2026.
Jazz Pharmaceuticals was a new Ruffer LLP position in Q2 2026.
Jazz Pharmaceuticals made up 0.21% of Ruffer LLP's portfolio in Q2 2026, its #88 holding.
Ruffer LLP first reported a position in Jazz Pharmaceuticals in Q2 2021 and has held it in 15 quarters since.
Ruffer LLP's Jazz Pharmaceuticals position peaked at $7.24M in Q4 2024.
646 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Ruffer LLP's 13F filing for Q2 2026, filed 30 Jul 2026.